Skip to Content

Becton Dickinson & Co

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation

Becton, Dickinson Should See Normalization in 2024 With Alaris' Return

Business Strategy and Outlook

After a tumultuous few years, Becton, Dickinson is undergoing course correction. The COVID-19 revenue windfall has been reinvested, which should lift the firm's core business growth in the upcoming years as the testing revenue fades. As Alaris has now returned to the market, the last remaining uncertainty has been resolved, although it is still to be seen whether the damage experienced by the franchise will be long-lasting or whether Alaris can regain its market-leading share rapidly.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BDX so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center